Biohaven Pharmaceutical Holding Company Ltd. (BHVN)’s Financial Results Comparing With Sutro Biopharma Inc. (NASDAQ:STRO)

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and Sutro Biopharma Inc. (NASDAQ:STRO), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of the two firms.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biohaven Pharmaceutical Holding Company Ltd. N/A 0.00 217.76M -5.61 0.00
Sutro Biopharma Inc. 38.42M 6.56 35.32M -2.21 0.00

Demonstrates Biohaven Pharmaceutical Holding Company Ltd. and Sutro Biopharma Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Biohaven Pharmaceutical Holding Company Ltd. 0.00% -201% -120.6%
Sutro Biopharma Inc. -91.93% 0% 0%

Liquidity

The Current Ratio and a Quick Ratio of Biohaven Pharmaceutical Holding Company Ltd. are 12 and 12. Competitively, Sutro Biopharma Inc. has 3.5 and 3.5 for Current and Quick Ratio. Biohaven Pharmaceutical Holding Company Ltd.’s better ability to pay short and long-term obligations than Sutro Biopharma Inc.

Analyst Recommendations

Ratings and Recommendations for Biohaven Pharmaceutical Holding Company Ltd. and Sutro Biopharma Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Biohaven Pharmaceutical Holding Company Ltd. 0 0 5 3.00
Sutro Biopharma Inc. 0 0 0 0.00

Biohaven Pharmaceutical Holding Company Ltd.’s upside potential is 32.26% at a $83.6 average price target.

Institutional and Insider Ownership

Institutional investors owned 91.4% of Biohaven Pharmaceutical Holding Company Ltd. shares and 75.3% of Sutro Biopharma Inc. shares. About 1.1% of Biohaven Pharmaceutical Holding Company Ltd.’s share are owned by insiders. On the other hand, insiders owned about 8.5% of Sutro Biopharma Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Biohaven Pharmaceutical Holding Company Ltd. 3.76% 23.81% 50.91% 27.74% 45.51% 27.53%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year Biohaven Pharmaceutical Holding Company Ltd. has stronger performance than Sutro Biopharma Inc.

Summary

On 6 of the 10 factors Sutro Biopharma Inc. beats Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.